[
    {
        "content": "* Akcea and Ionis announce acceptance of marketing applications in U.S.  EU and Canada for Volanesorsen for the treatment of FCS",
        "date": "11152017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S.  EU and Canada for Volanesorsen "
    },
    {
        "content": "* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen",
        "date": "11162017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen "
    },
    {
        "content": "* Ionis Pharmaceuticals Inc - co  \u200dDynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)\u200b",
        "date": "11092017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharma  \u200dDynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)\u200b "
    },
    {
        "content": "* Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017",
        "date": "11072017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals reports Q3 earnings per share $0.00 "
    },
    {
        "content": "* Ionis announces submission of marketing authorization application for inotersen to the European Medicines Agency Source text for Eikon: Further company coverage:",
        "date": "11032017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis submits marketing authorization application for Inotersen to the EMA "
    },
    {
        "content": "* Ionis announces submission of new drug application (NDA) for Inotersen to the U.S. fda Source text for Eikon: Further company coverage:",
        "date": "11062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis submits NDA for Inotersen to the U.S. FDA "
    },
    {
        "content": "* Ionis pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients with hereditary TTR Amyloidosis in the U.S.",
        "date": "10272017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients "
    },
    {
        "content": "* IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE",
        "date": "10182017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS "
    },
    {
        "content": "* IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE",
        "date": "10132017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE "
    },
    {
        "content": "* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada",
        "date": "09122017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada "
    },
    {
        "content": "* Ionis earns $40 million Spinraza regulatory milestone payment from Biogen",
        "date": "08302017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis earns $40 million Spinraza regulatory milestone payment from Biogen "
    },
    {
        "content": "* Ionis recommends shareholders reject the below-the-market mini-tender offer by TRC Capital Corporation",
        "date": "08242017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharma urges shareholders to reject tender offer by TRC Capital "
    },
    {
        "content": "* Ionis Pharmaceuticals Inc - Has retained all rights to inotersen and IONIS-FB-L(Rx).",
        "date": "08112017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis to independently advance inotersen and IONIS-FB-L Rx "
    },
    {
        "content": "* Ionis provides improved 2017 guidance following strong financial performance",
        "date": "08082017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis posts qtrly loss per share $0.09 "
    },
    {
        "content": "* Ionis earns $10 million milestone payment from Biogen for advancing a new program in its neurology collaboration",
        "date": "07172017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis receives $10 mln milestone payment from Biogen "
    },
    {
        "content": "* Data presented at peripheral nerve society meeting further support potential benefit of Inotersen\u200b",
        "date": "07102017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals presents \u200dnew data at peripheral nerve society meeting to support potential benefit of Inotersen\u200b "
    },
    {
        "content": "* On June 19  co entered into agreements with affiliates of Biomed Realty L.P - SEC filing",
        "date": "06222017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals entered into agreements with affiliates of Biomed Realty L.P "
    },
    {
        "content": "* Ionis Pharmaceuticals Inc - \u200dapproved to treat broad range of people with SMA\u200b",
        "date": "06012017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals says Spinraza approved in EU as treatment for SMA\u200b "
    },
    {
        "content": "* Reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L",
        "date": "05252017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L "
    },
    {
        "content": "* Ionis pharmaceuticals announces phase 3 neuro-ttr study of inotersen (ionis-ttr rx) meets both primary endpoints",
        "date": "05152017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharma announces Phase 3 NEURO-TTR study of inotersen meets both primary endpoints "
    },
    {
        "content": "* Ionis Pharmaceuticals provides corporate update at 2017 annual meeting of stockholders Source text for Eikon: Further company coverage:",
        "date": "05112017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals provides corporate update at 2017 annual meeting of stockholders "
    },
    {
        "content": "* Ionis reports financial results and highlights for first quarter 2017",
        "date": "05092017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals Q1 earnings per share $0.03 "
    },
    {
        "content": "* Files for potential stock shelf offering; amount undisclosed Source text for Eikon: Further company coverage:",
        "date": "04212017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals files for potential stock shelf offering "
    },
    {
        "content": "* Ionis enters into collaboration with ribo to advance rna-targeted therapeutics in china",
        "date": "04182017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis enters into collaboration with Ribo to advance RNA-targeted therapeutics in China "
    },
    {
        "content": "* Ionis Pharmaceuticals Inc - On March 27  2017  co's unit  Akcea Therapeutics Inc filed for an initial public offering of Akcea's common stock  Source: (http://bit.ly/2o0n2LQ) Further company coverage:",
        "date": "03272017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals' unit Akcea Therapeutics files for IPO "
    },
    {
        "content": "* Akcea and ionis announce positive results from pivotal study of volanesorsen in patients with familial chylomicronemia syndrome (fcs)",
        "date": "03062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Akcea and Ionis announce positive results from pivotal study of Volanesorsen "
    },
    {
        "content": "* Ionis' 2016 financial results outperform financial guidance",
        "date": "02282017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals Q4 GAAP earnings per share $0.21 "
    },
    {
        "content": "* Ionis earns $75 million from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx",
        "date": "02142017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis earns $75 mln from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx "
    },
    {
        "content": "* Ionis earns $5 million milestone payment from Biogen for advancing a new program under its broad neurology strategic collaboration  Source text for Eikon:  Further company coverage:",
        "date": "02022017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis earns $5 mln milestone payment from Biogen "
    },
    {
        "content": "* Ionis Pharmaceuticals significantly improves upon 2016 financial guidance",
        "date": "01062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharma expects to end 2016 with pro forma net operating income in low to mid $20 mln range "
    },
    {
        "content": "ZURICH  Jan 6 Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental treatments that aim to reduce cardiovascular risk in patients with high levels of lipoproteins  the Swiss drugmaker said on Friday.",
        "date": "01062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "Novartis joins forces with Ionis on cardiovascular treatments "
    },
    {
        "content": "ZURICH  Jan 6 Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental cardiovascular treatments in a deal which Ionis said could eventually be worth more than $1 billion.",
        "date": "01062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "UPDATE 1-Novartis joins forces with Ionis on cardiovascular treatments "
    },
    {
        "content": "* Ionis and Akcea enter into strategic collaboration with global pharmaceutical company to develop and commercialize akcea-apo(a)-l rx and akcea-apociii-l rx",
        "date": "01062017",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "BRIEF-Ionis  Akcea enter into strategic collaboration with Novartis "
    },
    {
        "content": "Ionis Pharmaceuticals Inc said on Monday its rare metabolic disorder drug for severe hypertriglyceridemia  characterized by elevated levels of a type of fat in the blood  met the main goal in a late-stage study.",
        "date": "12192016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "Ionis Pharma's rare metabolic disorder drug succeeds key study "
    },
    {
        "content": "* Ionis pharmaceuticals reports financial results and highlights for third quarter 2016",
        "date": "11092016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals Q3 EPS $0.06 "
    },
    {
        "content": "* Drug may get $1 bln-$2 bln in peak annual sales - Piper Jaffray",
        "date": "11072016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "UPDATE 3-Ionis  Biogen drug for fatal infant disorder succeeds in key study "
    },
    {
        "content": "* Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 cherish study in later-onset spinal muscular atrophy",
        "date": "11072016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study "
    },
    {
        "content": "Nov 7 Biogen Inc and Ionis Pharmaceuticals said their investigational treatment for a type of rare genetic muscular disorder met its main goal in an interim analysis of a late-stage study.",
        "date": "11072016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "Ionis and Biogen's muscular disorder treatment meets main goal "
    },
    {
        "content": "* Says on Sept 23  CHMP of EMA has granted accelerated assessment for Nusinersen MAA for spinal muscular atrophy  Source - http://bit.ly/2dnvyw6 Further company coverage:",
        "date": "09232016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals - CHMP granted accelerated assessment for Nusinersen MAA "
    },
    {
        "content": "* Ionis pharmaceuticals reports financial results and highlights for second quarter 2016",
        "date": "08092016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals reports Q2 loss per share $0.47 "
    },
    {
        "content": "* Ionis Pharmaceuticals licenses first oral antisense drug acting locally in the GI tract to Janssen",
        "date": "07192016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals licenses oral antisense drug to Janssen "
    },
    {
        "content": "NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices  freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni.",
        "date": "06072016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "Gilead escapes liability in hepatitis C patent fight with Merck "
    },
    {
        "content": "NEW YORK  June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices  freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni.",
        "date": "06072016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck "
    },
    {
        "content": "Ionis Pharmaceuticals Inc's shares plunged 40 percent on Thursday  wiping out over $900 million from its market value  after the company said GlaxoSmithKline Plc had scrapped plans to test their heart drug in a late-stage trial.",
        "date": "05262016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "Ionis shares plummet as GSK scraps heart drug trial plans "
    },
    {
        "content": "May 26 Ionis Pharmaceuticals Inc's  shares plunged 40 percent on Thursday  wiping out over $900 million from its market value  after the company said GlaxoSmithKline Plc had scrapped plans to test their heart drug in a late-stage trial.",
        "date": "05262016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "UPDATE 1-Ionis shares plummet as GSK scraps heart drug trial plans "
    },
    {
        "content": "May 26 Ionis Pharmaceuticals Inc's  shares plunged 40 percent on Thursday  wiping out over $900 million from its market value  after the company said GlaxoSmithKline Plc had scrapped plans to test their heart drug in a late-stage trial.",
        "date": "05262016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "Ionis shares slump 40 pct as GSK scraps heart drug trial plans "
    },
    {
        "content": "* Currently evaluating IONIS-TTR Rx in an ongoing Phase 3 study  neuro-ttr  in patients with transthyretin familial amyloid polyneuropathy",
        "date": "05262016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals provides update on IONIS-TTR Rx program "
    },
    {
        "content": "* Ionis reports financial results and highlights for first quarter 2016",
        "date": "05042016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis reports Q1 loss per share $0.52 "
    },
    {
        "content": "* Ionis Pharmaceuticals and Kastle Therapeutics announce acquisition of Kynamro",
        "date": "05032016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals and Kastle Therapeutics to buy Kynamro "
    },
    {
        "content": "* Earned a milestone payment of $7.5 million from Biogen for advancing Nusinersen in open-label extension study  SHINE  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "03312016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "topStory",
        "symbol": "IONS",
        "title": "BRIEF-Ionis Pharmaceuticals earns milestone payment of $7.5 mln from Biogen "
    },
    {
        "content": "SAN JOSE  Calif. /NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc  to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03252016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute "
    },
    {
        "content": "SAN JOSE  Calif. /NEW YORK  March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.",
        "date": "03252016",
        "name": "Ionis Pharmaceuticals Inc",
        "news_type": "normal",
        "symbol": "IONS",
        "title": "UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute "
    }
]